- Lilly will start Phase 3 trials for eloralintide in obesity treatment next month.
- Eloralintide showed 9.5% to 20.1% weight reduction in a 48-week Phase 2 trial.
- The trial involved 263 adults with obesity or overweight and no type 2 diabetes.
- Eloralintide improved cardiometabolic factors like waist circumference and blood pressure.
Phase 2 Trial Results
Eli Lilly's Phase 2 trial of eloralintide, a selective amylin receptor agonist, involved 263 adults with obesity or overweight and at least one obesity-related comorbidity, excluding type 2 diabetes. Over 48 weeks, eloralintide demonstrated significant weight reductions ranging from 9.5% to 20.1%, compared to 0.4% with placebo. The trial's primary endpoint was met, showcasing the drug's efficacy.
Cardiometabolic Improvements
Eloralintide also delivered clinically meaningful improvements in secondary endpoints, including reductions in body weight and body mass index. Additionally, it positively impacted cardiometabolic risk factors such as waist circumference, blood pressure, lipid profiles, glycemic control, and inflammation markers.
Future Plans
Lilly plans to initiate Phase 3 clinical studies of eloralintide as a monotherapy for obesity treatment by the end of the year. The company is also exploring its use as a complementary treatment to incretin therapy.
Study Design
The Phase 2 study was a 48-week, randomized, double-blind, placebo-controlled trial. Participants were randomized in a 2:1:1:1:2:1:2 ratio to receive either placebo, 1 mg, 3 mg, 6 mg, or 9 mg eloralintide, or an eloralintide dose escalation of 6/9 mg or 3/6/9 mg. The primary objective was to demonstrate eloralintide's superiority over placebo in percent change in body weight from baseline at 48 weeks.
